An observational study in Choroidal Neovascularization, Visual Field, Visual Acuity, sponsored by University Hospital, Limoges. Withdrawn at 1 site in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by University Hospital, Limoges · Observational
ARMD is the main cause of visual disability after 50 years old in France. Patients with active neovascular ARMD are treated with intravitreal injections of antiVEGF. Reinjections criteria are decrease of best corrected visual acuity or active neovascularization's signs (mostly found on macular OCT but also on angiography when necessary).
The aim of this study is to evaluate the link between active neovascularization found on OCT and eye fixation quality measured with microperimetry in ARMD patients treated with antiVEGF.
Quality of eye fixation and exudative signs presents or not present on OCT will be gathered at each consultation over the two-years follow-up for each patient. The mean central retinal sensitivity, the best corrected visual acuity and the bivariate contour ellipse area will also be gathered.
In case no link will be found, for instance bad fixation quality without exudative signs on OCT or good fixation stability despite exudative signs on OCT, microperimetry should have an interest to improve reinjections criteria with a treatment more suitable to the patient.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →University Hospital, Limoges is the lead sponsor of 264 studies on the registry; 38 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with active neovascular ARMD treated with antiVEGF
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
fixation stability measured by microperimetry and exudative signs on OCT
quality of eye fixation and exudative signs presents or not present on OCT will be gathered at each consultation over the two-years follow-up. The fixation stability is classified as follows: * Stable if more than 75% of the fixation points are contained inside the circle of 2 degrees of diameter * Relatively unstable if more than 75% of the fixation points are contained within the circle of 4 degrees of diameter and less than 75% contained within that of 2 degrees of diameter * Unstable if less than 75% of the fixation points are contained within the circle of 4 degrees of diameter
Time frame: 2 years
Bivariate Contour Ellipse Area (BCEA) value
BCEA will be gathered at each consultation over the two-years follow-up
Time frame: 2 years
mean central retinal sensitivity
mean central retinal sensitivity will be gathered at each consultation over the two-years follow-up
Time frame: 2 years
Best Corrected Visual Acuity (BCVA)
BCVA will be gathered at each consultation over the two-years follow-up
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2018 to primary completion in Jan 2019, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Choroidal Neovascularization →
University Hospital, Limoges →